While Pacira BioSciences Inc has underperformed by -0.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PCRX rose by 27.28%, with highs and lows ranging from $27.64 to $16.64, whereas the simple moving average fell by -1.47% in the last 200 days.
On November 17, 2025, H.C. Wainwright started tracking Pacira BioSciences Inc (NASDAQ: PCRX) recommending Buy. A report published by Truist on July 25, 2025, Upgraded its rating to ‘Buy’ for PCRX. Truist also Upgraded PCRX shares as ‘Hold’, setting a target price of $25 on the company’s shares in a report dated January 30, 2025. Truist August 13, 2024d the rating to Sell on August 13, 2024, and set its price target from $30 to $8. RBC Capital Mkts August 12, 2024d its ‘Outperform’ rating to ‘Sector Perform’ for PCRX, as published in its report on August 12, 2024. Piper Sandler also rated the stock as ‘Neutral’.
Analysis of Pacira BioSciences Inc (PCRX)
Further, the quarter-over-quarter increase in sales is 6.49%, showing a positive trend in the upcoming months.
One of the most important indicators of Pacira BioSciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 2.90% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.78, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and PCRX is recording 633.10K average volume. On a monthly basis, the volatility of the stock is set at 5.07%, whereas on a weekly basis, it is put at 3.62%, with a gain of 0.71% over the past seven days. Furthermore, long-term investors anticipate a median target price of $30.17, showing growth from the present price of $23.98, which can serve as yet another indication of whether PCRX is worth investing in or should be passed over.
How Do You Analyze Pacira BioSciences Inc Shares?
The Drug Manufacturers – Specialty & Generic market is dominated by Pacira BioSciences Inc (PCRX) based in the USA. When comparing Pacira BioSciences Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 53.75, there is a growth in quarterly earnings of 103.93%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.27%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 114.16% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
